U.S., Aug. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07107802) titled 'Phase 1 Single Ascending Dose Study With ATX101' on July 25.
Brief Summary: The main objective of this study is to assess the safety and tolerability of intravenously administered ATX101 in healthy adults following single ascending doses of ATX101. The pharmacokinetic profile of BI 764198 (ATX101 drug substance) and its metabolites will also be investigated.
Study Start Date: July 19
Study Type: INTERVENTIONAL
Condition:
Healthy Participants
Intervention:
DRUG: ATX101
Single intravenous dose
DRUG: Placebo
Single intravenous dose
Recruitment Status: RECRUITING
Sponsor: Aurobac Therapeutics SAS
Disclaimer: Curated by HT Syn...